Drug Trial Radar · NCT05848440
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
Last checked: Nov 19, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 2, 2023
Primary completion
Nov 13, 2023
Study completion Nov 13, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- May 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
AZD9550Drug
Participants will be administered AZD9550 subcutaneously.
AZD9550Drug
Participants will be administered AZD9550 intravenously.
PlaceboDrug
Participants will be administered matching volumes of placebo subcutaneously or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Throughout the study (up to 6 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Harrow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.